NCT00788697View on ClinicalTrials.gov

SonoVue®-Enhanced Ultrasound Versus Unenhanced US for Focal Liver Lesion Characterization

PHASE3CompletedINTERVENTIONAL
Enrollment

349

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Liver Neoplasms
Interventions
DRUG

SonoVue-enhanced ultrasound

Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)

OTHER

Unenhanced ultrasound

-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None

Trial Locations (1)

08540

Bracco Diagnostics Inc, Princeton

Sponsors
All Listed Sponsors
lead

Bracco Diagnostics, Inc

INDUSTRY